Skip to main content
AMRN
NASDAQ Life Sciences

Amarin Reports Strong Q1 2026 Results with Positive Operating Cash Flow and Settles Antitrust Class Actions

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
8
Price
$13.96
Mkt Cap
$290.517M
52W Low
$9.44
52W High
$20.9
Market data snapshot near publication time

summarizeSummary

Amarin reported improved Q1 2026 financial results, including a shift to positive operating cash flow and reduced net loss, driven by cost controls and international growth. The company also settled multiple antitrust class action lawsuits.


check_boxKey Events

  • Achieved Positive Operating Cash Flow

    Net cash provided by operating activities was $6.4 million for Q1 2026, a significant improvement from net cash used of $12.5 million in Q1 2025, indicating enhanced operational efficiency and financial stability.

  • Reduced Net Loss

    The company reported a net loss of $10.5 million for Q1 2026, a reduction from a net loss of $15.7 million in Q1 2025, and basic/diluted loss per share improved to ($0.03) from ($0.04).

  • Revenue Growth Driven by International Partnerships

    Total revenue increased by 7% to $45.1 million in Q1 2026. Licensing and royalty revenue surged by 84% to $1.8 million, and RoW product revenue significantly increased to $2.8 million, reflecting the success of the European partnering model and developing ex-U.S. markets.

  • Significant Reduction in Operating Expenses

    Selling, general and administrative (SG&A) expenses decreased by 42% to $21.1 million, primarily due to cost savings from the Global Restructuring Plan initiated in June 2025.


auto_awesomeAnalysis

Amarin Corporation plc reported a significant financial turnaround in Q1 2026, achieving positive net cash flow from operating activities of $6.4 million, a substantial improvement from a net cash outflow of $12.5 million in the prior year period. This was driven by a 42% reduction in selling, general, and administrative (SG&A) expenses, reflecting the impact of the Global Restructuring Plan initiated in June 2025. Total revenue increased by 7% year-over-year to $45.1 million, with notable growth in licensing and royalty revenue (up 84%) and Rest of World (RoW) product revenue, indicating successful execution of its international partnering strategy. The company also announced a confidential settlement agreement for six antitrust class action lawsuits, removing a significant legal overhang. While gross margin decreased due to a shift in customer mix towards lower-margin partner sales, the overall financial health shows improvement and strategic progress. Ongoing patent litigation with Hikma at the Supreme Court and a lawsuit by the former CEO remain as notable risks.

At the time of this filing, AMRN was trading at $13.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $290.5M. The 52-week trading range was $9.44 to $20.90. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed AMRN - Latest Insights

AMRN
Apr 29, 2026, 5:38 PM EDT
Source: Reuters
Importance Score:
9
AMRN
Apr 29, 2026, 7:13 AM EDT
Source: Wiseek News
Importance Score:
8
AMRN
Apr 29, 2026, 7:06 AM EDT
Filing Type: 10-Q
Importance Score:
8
AMRN
Apr 29, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
AMRN
Apr 10, 2026, 5:00 PM EDT
Filing Type: DEF 14A
Importance Score:
8
AMRN
Apr 08, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
AMRN
Mar 30, 2026, 5:57 PM EDT
Filing Type: PRE 14A
Importance Score:
8
AMRN
Mar 02, 2026, 5:31 PM EST
Filing Type: 10-K
Importance Score:
8
AMRN
Feb 25, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
8
AMRN
Jan 08, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
9